Knott David M Jr 13F holdings
Knott David M Jr reported 83 positions with a total reported value of $189.2M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-12. Top holdings by reported value: GOOGL Alphabet Inc CL A (17.1%), APO Apollo Global Management, Inc. (14.1%), SNDX Syndax Pharmaceutical, Inc. (5.1%), XERS Xeris Biopharma Holdings, Inc. (4.4%), TVTX Travere Therapeutics, Inc. (4.4%). Against 2026-03-31 it opened 9 new positions and exited 10. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Knott David M Jr files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
25 largest of 83 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| GOOGL Alphabet Inc CL A | 91,720 | $32.4M | 17.1% |
| APO Apollo Global Management, Inc. | 225,000 | $26.6M | 14.1% |
| SNDX Syndax Pharmaceutical, Inc. | 437,245 | $9.6M | 5.1% |
| XERS Xeris Biopharma Holdings, Inc. | 1,060,000 | $8.4M | 4.4% |
| TVTX Travere Therapeutics, Inc. | 147,282 | $8.4M | 4.4% |
| PTGX Protagonist Therapeutics, Inc | 63,000 | $7.7M | 4.1% |
| BBIO Bridgebio Pharma, Inc. | 92,850 | $6.9M | 3.7% |
| IOVA Iovance Biotherapeutics, Inc. | 1,600,000 | $6.7M | 3.5% |
| ALKS Alkermes PLC | 121,759 | $6.4M | 3.4% |
| JPM JPMorgan Chase & Co. | 18,098 | $5.9M | 3.1% |
| Janus Henderson AAA CLO ETF | 93,528 | $4.7M | 2.5% |
| LPLA LPL Financial Holdings Inc. | 16,500 | $4.6M | 2.5% |
| COGT Cogent Biosciences Inc. | 111,081 | $4.3M | 2.3% |
| TGTX TG Therapeutics, Inc. | 66,839 | $3.7M | 1.9% |
| CLST Catalyst Pharmaceuticals, Inc. | 114,000 | $3.6M | 1.9% |
| AGIO Agios Pharmaceutical, Inc. | 95,058 | $3.5M | 1.9% |
| Viridian Therapeutics, Inc. | 181,000 | $3.3M | 1.8% |
| RLMD Relmada Therapeutics, Inc. | 451,000 | $3.1M | 1.6% |
| RCUS Arcus Biosciences, Inc. | 81,241 | $2.5M | 1.3% |
| Cybin Inc | 370,000 | $2.4M | 1.3% |
| SPDR S&P Biotech ETF | 15,000 | $2.4M | 1.3% |
| RZLT Rezolute, Inc. | 370,000 | $1.9M | 1.0% |
| AB AllianceBernstein Holding L.P. | 48,000 | $1.7M | 0.9% |
| MDGL Madrigal Pharmaaceuticals, Inc. | 3,000 | $1.6M | 0.9% |
| ATRC AtriCure, Inc. | 51,400 | $1.4M | 0.8% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 9 in all · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| CLST Catalyst Pharmaceuticals, Inc. | 114,000 | $3.6M | 1.9% |
| SPRB Spruce Biosciences, Inc. | 20,000 | $1.1M | 0.6% |
| INSM Insmed Incorporated | 4,253 | $453.5K | 0.2% |
| LBRX LB Pharmaceuticals, Inc. | 12,965 | $420.8K | 0.2% |
| CDNA CareDx, Inc. | 13,630 | $388.5K | 0.2% |
| QTTB Q32 Bio Inc | 30,412 | $387.4K | 0.2% |
| ELVN Enliven Therapeutics, Inc. | 6,183 | $313.8K | 0.2% |
| BSX Boston Scientific Corporation | 6,000 | $256.1K | 0.1% |
| Occidential Pertro Wts exp. 8/3/27 | 194 | $4.3K | <0.1% |
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 10 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| CPRX Catalyst Pharmaceuticals, Inc. | 120,000 | $3.0M | 1.8% |
| Arcellx Inc | 19,433 | $2.2M | 1.3% |
| CYTK Cytokinetics, Incorporated | 23,644 | $1.6M | 0.9% |
| Centessa Pharmaceuticals PLC | 39,000 | $1.5M | 0.9% |
| ADMA ADMA Biologics, Inc. | 60,200 | $542.4K | 0.3% |
| Biohaven Pharmaceutical Holding Co. Ltd | 60,720 | $513.7K | 0.3% |
| EOLS Evolus, Inc. | 99,338 | $408.3K | 0.2% |
| LENZ LENZ Therapeutics, Inc. | 33,732 | $308.6K | 0.2% |
| JSPR Jasper Therapeutics, Inc. | 160,789 | $140.9K | <0.1% |
| MREO Mereo BioPharm Group PLC | 300,337 | $99.1K | <0.1% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| CGEM Cullinan Therapeutics, Inc. | 24,200 | 69,182 | +185.9% | $1.3M |
| MDGL Madrigal Pharmaaceuticals, Inc. | 2,000 | 3,000 | +50.0% | $1.6M |
| TVTX Travere Therapeutics, Inc. | 140,633 | 147,282 | +4.7% | $8.4M |
| SNDX Syndax Pharmaceutical, Inc. | 422,000 | 437,245 | +3.6% | $9.6M |
| ARDX Ardelyx, Inc. | 207,000 | 263,168 | +27.1% | $1.3M |
| COGT Cogent Biosciences Inc. | 104,000 | 111,081 | +6.8% | $4.3M |
| BBIO Bridgebio Pharma, Inc. | 90,000 | 92,850 | +3.2% | $6.9M |
| VSTM Verastem Inc. | 104,000 | 155,000 | +49.0% | $592.1K |
| RARE Ultragenyx Pharmaceutical Inc. | 33,069 | 38,069 | +15.1% | $1.3M |
| CNTB Connect Biopharma Holdings Limited | 387,835 | 444,862 | +14.7% | $1.1M |
| Cybin Inc | 350,000 | 370,000 | +5.7% | $2.4M |
| ALKS Alkermes PLC | 120,000 | 121,759 | +1.5% | $6.4M |
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| TGTX TG Therapeutics, Inc. | 90,001 | 66,839 | -25.7% | $3.7M |
| BMY Bristol-Myers Squibb Company | 13,622 | 2,000 | -85.3% | $115.2K |
| JPM JPMorgan Chase & Co. | 19,477 | 18,098 | -7.1% | $5.9M |
| Occidental Petroleum Corporation | 663 | 469 | -29.3% | $22.8K |
CIK 1892770 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
